학술논문
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
13652141